Octreotide: Supply issue
The supplier of the funded octreotide 50 mcg and 500 mcg per ml injections (Pfizer) continues to experience issues with the supply of this medicine.
To ensure continuity of supply, Pfizer has notified PHARMAC that they've sourced alternatives.
This will be listed from 1 September 2020
- Octreotide GH inj 50 mcg per ml, 1 ml ampoule (Pharmacode 2595907)
- Octreotide GH inj 500 mcg per ml, 1 ml ampoule (Pharmacode 2595893)
Pfizer advises that these products can be ordered from OneLink.
These products have not been approved by Medsafe and will therefore be supplied under Section 29.
They replace the existing section 29 medicines:
- Octreotide MaxRx Inj 50 mcg per ml, 1 ml vial (Pharmacode 2396939)
- Octreotide SUN Inj 500 mcg per ml, 1 ml vial (Pharmacode 2586002).
We will delist these medicines in about 6 months. This allows time for any remaining in the supply chain to be used up.
Who to contact
If you have any questions, contact the Pfizer customer service team on 0800 736 363
Last updated: 20 August 2020